Skip to main content
. Author manuscript; available in PMC: 2021 Feb 5.
Published in final edited form as: J Am Chem Soc. 2020 Jan 23;142(5):2140–2144. doi: 10.1021/jacs.9b11548

Figure 3.

Figure 3.

Antiviral efficacy of VIQKI-I456F and VIQKI-I454F/I456F against RSV or HPIV3. Peptide activity against (A) RSV or (B) HPIV3 was determined by plaque-reduction assay in infected Hep-2 cell monolayers. Data are expressed as mean ± standard deviation (n=3 separate experiments).